GRM5 and fragile X syndrome: We chose to test the effect of KD on sleep EEG in Fmr1KO mice because the KD is proving therapeutic for many disease states that are comorbid with FXS, including epilepsy and autism; individuals with FXS present with an abnormal fatty acid profile [103]; and our prior work indicated that KD was as or more effective than the best metabotropic glutamate receptor 5 (mGluR5) inhibitors tested in the AGS assay.